Literature DB >> 1868026

Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer.

C J Rodenburg1, K Nooter, H Herweijer, C Seynaeve, R Oosterom, G Stoter, J Verweij.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1868026     DOI： 10.1093/oxfordjournals.annonc.a057941

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  11 in total

1.  Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies.

Authors:  A K Sood; J I Sorosky; R C Squatrito; J S Skilling; B Anderson; R E Buller
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

2.  Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma.

Authors:  G H Mickisch; M A Noordzij; A vd Gaast; P Gebreamlack; K U Köhrmann; E Mogler-Drautz; H Kupper; F H Schröder
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 3.  Development of multidrug-resistance convertors: sense or nonsense?

Authors:  L van Zuylen; K Nooter; A Sparreboom; J Verweij
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

4.  Vinblastine and erythromycin: an unrecognized serious drug interaction.

Authors:  S W Tobe; L L Siu; S A Jamal; K L Skorecki; G F Murphy; E Warner
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour.

Authors:  W Van de Vrie; E E Gheuens; N M Durante; E A De Bruijn; R L Marquet; A T Van Oosterom; A M Eggermont
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 6.  Chemoresistance of renal cell carcinoma: 1986-1994.

Authors:  G H Mickisch
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

7.  P glycoprotein (P-gp) and drug resistance--time for reappraisal?

Authors:  S B Kaye
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

8.  Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study.

Authors:  R González-Manzano; J Cid; A Brugarolas; C C Piasecki
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

9.  Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia.

Authors:  T Colombo; O Gonzalez Paz; M D'Incalci
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

10.  Activity of cyclosporins as resistance modifiers in primary cultures of human haematological and solid tumours.

Authors:  H Fridborg; B Jonsson; P Nygren; K Csoka; K Nilsson; G Oberg; J Kristensen; J Bergh; B Tholander; L Olsen
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.